DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial
Daiichi Sankyo and AstraZeneca’s DS-8201 demonstrated an impressive 14.8 month median duration of response and 16.4 month median progression-free survival…